Infrared therapy noncovered
This article was originally published in The Gray Sheet
More than 4,000 comments from patients and clinicians supporting market-leading Anodyne infrared therapy could not sway CMS to reverse its proposed noncoverage decision for its use to treat peripheral sensory neuropathy, wounds, skin ulcers and related symptoms (1"The Gray Sheet" Feb. 6, 2006, p. 5). CMS' final national coverage decision, released Oct. 24, cites lack of evidence of the treatment's durability, poor methodology in studies with positive results, significant placebo effect and concerns about adverse events reported to FDA...
You may also be interested in...
CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.